Currently, Atyr Pharma Inc [ATYR] is trading at $3.44, up 5.20%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The ATYR shares have gain 6.17% over the last week, with a monthly amount glided 10.97%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Atyr Pharma Inc [NASDAQ: ATYR] stock has seen the most recent analyst activity on February 18, 2025, when Leerink Partners initiated its Outperform rating and assigned the stock a price target of $16. On October 04, 2024, Wells Fargo initiated with a Overweight rating and assigned a price target of $17 on the stock. Jefferies started tracking the stock assigning a Buy rating and suggested a price target of $9 on September 05, 2024. Oppenheimer downgraded its rating to a Perform. RBC Capital Mkts started tracking with a Outperform rating for this stock on October 12, 2021, and assigned it a price target of $22. In a note dated September 21, 2021, Piper Sandler initiated an Overweight rating and provided a target price of $19 on this stock.
This stock has fluctuated between a low of $1.42 and a high of $4.66 over the last 52 weeks. Atyr Pharma Inc [NASDAQ: ATYR] shares were valued at $3.44 at the most recent close of the market.
Analyzing the ATYR fundamentals
Trailing Twelve Months sales for Atyr Pharma Inc [NASDAQ:ATYR] were 0.00M which represents -100.00% decline. To continue investigating profitability, this company’s Return on Assets is posted at -0.65, Equity is -0.87 and Total Capital is -0.77. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.17.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Atyr Pharma Inc [NASDAQ:ATYR] is 7.79. Also, the Quick Ratio is 7.79, while the Cash Ratio stands at 0.97.
Transactions by insiders
Recent insider trading involved Gross Jane A, Director, that happened on Mar 17 ’25 when 3750.0 shares were purchased. Chief Financial Officer, Broadfoot Jill Marie completed a deal on Feb 04 ’25 to sell 1254.0 shares. Meanwhile, General Counsel DENYES NANCY sold 899.0 shares on Feb 04 ’25.
